Edasalonexent

CAS No. 1204317-86-1

Edasalonexent( CAT-1004 | CAT1004 )

Catalog No. M10746 CAS No. 1204317-86-1

Edasalonexent (CAT-1004) is a bifunctional, orally administered small molecule that covalently links 2 compounds known to inhibit NF‐κB, salicylic acid and docosahexaenoic acid (DHA).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 254 In Stock
2MG 140 In Stock
5MG 235 In Stock
10MG 376 In Stock
25MG 676 In Stock
50MG 1042 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Edasalonexent
  • Note
    Research use only, not for human use.
  • Brief Description
    Edasalonexent (CAT-1004) is a bifunctional, orally administered small molecule that covalently links 2 compounds known to inhibit NF‐κB, salicylic acid and docosahexaenoic acid (DHA).
  • Description
    Edasalonexent (CAT-1004) is a bifunctional, orally administered small molecule that covalently links 2 compounds known to inhibit NF‐κB, salicylic acid and docosahexaenoic acid (DHA); significantly inhibits NF-κB p65-dependent inflammatory responses as well as downstream proinflammatory genes modulated by p65 in the golden retriever DMD model; Edasalonexent is hydrolyzed by FAAH to release salicylic acid and DHA intracellularly and to suppress activated NF-κB.Other Indication Phase 2 Clinical.
  • In Vitro
    Edasalonexent is an orally administered small molecule in which salicylic acid and docosahexaenoic acid (DHA) are covalently conjugated through an ethylenediamine linker and that is designed to synergistically leverage the ability of both of these compounds to inhibit NF-κB. Edasalonexent significantly inhibits NF-κB p65-dependent inflammatory responses as well as downstream proinflammatory genes modulated by p65 in the golden retrieverduchenne muscular dystrophy (DMD) model.
  • In Vivo
    The treatment of mdx mice with Edasalonexent for 20 weeks results in reduced susceptibility of the extensor digitorum longus muscle to eccentric contraction-induced injury.
  • Synonyms
    CAT-1004 | CAT1004
  • Pathway
    Apoptosis
  • Target
    NF-κB
  • Recptor
    NF-κB
  • Research Area
    Other Indications
  • Indication
    Other Disease

Chemical Information

  • CAS Number
    1204317-86-1
  • Formula Weight
    490.688
  • Molecular Formula
    C31H42N2O3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 120 mg/mL (244.56 mM)
  • SMILES
    O=C(NCCNC(CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)=O)C1=CC=CC=C1O
  • Chemical Name
    N-[2-[[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]amino]ethyl]-2-hydroxybenzamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Donovan JM, et al. J Clin Pharmacol. 2017 May;57(5):627-639. 2. Vu CB, et al. J Med Chem. 2016 Feb 11;59(3):1217-31.
molnova catalog
related products
  • SR12460

    SR12460 (SR-12460) is a novel NF-κB essential modulator (NEMO)-binding domain (NBD) mimetic for inhibiting IKK/NF-κB activation.

  • Myrislignan

    Myrislignan has anti-inflammatory and anti-cancer activities it inhibited NF-κB signalling pathway activation inhibited the proliferation of A549 cells in a dose- and time-dependent manner it also significantly induced apoptosis and cell cycle arrest in A549 cells.

  • Cynaropicrin

    Cynaropicrin, a sesquiterpene lactone found in artichoke (Cynara scolymus), has anti-hepatitis C and trypanosome activity and inhibits NF-κB activation.